Ligand Pharma (LGND) Tops Q3 EPS by 3c

Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $0.62, $0.03 better than the analyst estimate of $0.59. Revenue for the quarter came in at $21.6 million versus the consensus estimate of $23.13 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Jefferies Downgrades Sunway Healthcare Holdings (SUNMED:MK) to Hold
• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance